#Israel #NESS ZIONA #Matricelf Ltd #TASE MTLF #Ron Mayron

Matricelf Ltd. Welcomes Ron Mayron as New Chairman of the Board

Matricelf Ltd., a pivotal player in the biotechnology sector known for developing autologous engineered tissue therapies, has officially announced the appointment of Ron Mayron as the Active Chairman of the Board. This strategic move, confirmed by shareholder approval, is expected to propel the company's vision forward as it embarks on critical clinical milestones.

Background on Ron Mayron

Ron Mayron brings with him a wealth of experience, holding a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. Since 2015, he has been at the helm of RonMed Ltd. as its CEO and owner, showcasing his leadership across various health-related sectors. Over the past five years, Mayron has also contributed his expertise to a range of public and private life sciences ventures. These include prominent names such as SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, and DNA Biomedical Solutions, among others. His board level involvement cuts across the biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms, highlighting his versatility and depth of knowledge.

Despite his extensive industry affiliation, Mayron confirmed his impartiality, stating he does not hold any shares or convertible securities of Matricelf Ltd. at the time of his appointment. This declaration underscores his commitment to transparency and governance, which are crucial in today’s corporate landscape.

A Vision for the Future

Gil Hakim, CEO of Matricelf, expressed excitement about Mayron's leadership, stating, "Ron brings significant strategic, operational and board level expertise in scaling healthcare companies and navigating complex regulatory and capital markets environments. His leadership will be instrumental as we advance toward our first in human clinical milestones and expand our platform into additional neurological indications."

With Matricelf pioneering personalized autologous engineered neural tissue implant programs aimed at treating spinal cord injuries, the company is also intent on branching out into other neurological applications. Mayron emphasized the significance of Matricelf's mission, noting, "Matricelf represents a compelling convergence of cutting-edge regenerative medicine, strong scientific leadership, and meaningful clinical ambition. I look forward to working with management and the Board to support disciplined execution, strategic partnerships, and long-term value creation."

About Matricelf Ltd.

Matricelf Ltd. operates in the regenerative medicine field, focusing its efforts on personalizing engineered tissue therapies through proprietary stem cell and hydrogel technologies. Its leading initiative addresses spinal cord injuries while also exploring additional neurological challenges, indicating a robust pipeline and commitment to innovation in healthcare.

As the company moves forward under the guidance of Ron Mayron, it is set to navigate both the challenges of clinical trials and the complexities of regulatory environments, aiming for breakthroughs that could redefine treatment avenues in modern medicine.

In conclusion, the appointment of Ron Mayron as chairman marks a pivotal moment for Matricelf Ltd., enriching its leadership landscape and setting a promising trajectory for innovation and growth in the field of regenerative medicine.